β
Outcome MeasureQuality of Life

WSAS

Work and Social Adjustment Scale

3 Papers in Blossom

Clinical Thresholds

040
Subclinical
Score 0–9
Significant impairment
Score 10–19
Moderately severe
Score 20–40

Outcome Data Across Studies

Reported results for WSAS across 3 studies with quantitative data.

Outcome data across 11 study arm–timepoint observations
SD
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + placebo(experimental)42——Δ——
Trial of Psilocybin versus Escitalopram for Depression
2021Secondary
Psilocybin + escitalopram(active_comparator)42——Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + placebo(experimental)0——Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + placebo(experimental)42—-12.1Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + placebo(experimental)90—-12.1Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + placebo(experimental)180—-12.7Δ—0.001
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + escitalopram(active_comparator)0——Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + escitalopram(active_comparator)42——Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + escitalopram(active_comparator)90—-1.0Δ——
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial
2024Secondary
Psilocybin + escitalopram(active_comparator)180—-3.1Δ—0.001

Papers Using WSAS

Open Accessindividual

Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

This open-label trial (n=12) conducted at Sheppard Pratt Hospital finds that psilocybin (25mg) significantly decreases depressive symptoms in patients with severe treatment-resistant depression (TRD) at 3 weeks (MADRS −15.8) and 12 weeks (MADRS −17.2) post-treatment. Exploratory analyses suggest the Oceanic Boundlessness dimension correlates with antidepressant responses, while patients with comorbid PTSD show reduced antidepressant effects.

Published
Journal
American Journal of Psychiatry
Authors
Aaronson, S. T., Van Der Vaart, A., Miller, T., Lapratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Suppes, T., Sackeim, H. A.
Open Accessindividual

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

This 6-month follow-up of a Phase II, double-blind, randomised controlled trial (n=59) finds sustained improvements in depressive symptoms for both psilocybin therapy (PT) and escitalopram treatment (ET) for moderate-to-severe major depressive disorder (MDD). PT shows greater improvements in psychosocial functioning, meaning in life, and psychological connectedness compared to ET at the 6-month follow-up.

Published
Journal
EClinicalMedicine
Authors
Erritzoe, D., Barba, T., Greenway, K. T., Murphy-Beiner, A., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Baker-Jones, M., Nutt, D. J., Weiss, B., Carhart-Harris, R. L.
Open Accessindividual

Trial of Psilocybin versus Escitalopram for Depression

This double-blind placebo-controlled study (n=59) compared psilocybin (2x25mg; 3 weeks apart) to escitalopram (SSRI) over a six-week period and found large improvements in depression scores for those suffering from depression (MDD) in both groups. On the main measure of depression, the QIDS-SR-16, there was no significant difference between both groups. The study did find significant differences, favoring psilocybin, on the HAM-D-17, MADRS, avoidance, flourishing, wellbeing, and suicidality.

Published
Journal
New England Journal of Medicine
Authors
Carhart-Harris, R. L., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy, R., Murphy-Beiner, A., Martell, J., Blemings, A., Erritzoe, D., Nutt, D. J.

Quick Facts

Full Name
Work and Social Adjustment Scale
Domain
Quality of Life
Papers Indexed
3
Score Range
0–40
Interpretation
Lower = better
All Measures